Our top pick for
Kodiak Sciences Inc is a biotechnology business based in the US. Kodiak Sciences shares (KOD) are listed on the NASDAQ and all prices are listed in US Dollars. Kodiak Sciences employs 48 staff and has a market cap (total outstanding shares value) of USD$3.5 billion.
Since the stock market crash in March caused by coronavirus, Kodiak Sciences's share price has had significant positive movement.
Its last market close was USD$113.56, which is 48.68% up on its pre-crash value of USD$58.28 and 219.94% up on the lowest point reached during the March crash when the shares fell as low as USD$35.4939.
If you had bought USD$1,000 worth of Kodiak Sciences shares at the start of February 2020, those shares would have been worth USD$737.30 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,804.47.
|Latest market close||USD$113.56|
|52-week range||USD$18.52 - USD$81|
|50-day moving average||USD$59.2323|
|200-day moving average||USD$55.0036|
|Wall St. target price||USD$82.56|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.495|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-23)||-9.53%|
|1 month (2020-10-30)||25.05%|
|3 months (2020-08-28)||122.10%|
|6 months (2020-05-29)||75.76%|
|1 year (2019-11-29)||283.65%|
|2 years (2018-11-30)||1,127.68%|
|3 years (2017-11-26)||N/A|
|5 years (2015-11-26)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-20.05%|
|Return on equity TTM||-41.34%|
|Market capitalisation||USD$3.5 billion|
TTM: trailing 12 months
There are currently 3.7 million Kodiak Sciences shares held short by investors – that's known as Kodiak Sciences's "short interest". This figure is 9.2% up from 3.4 million last month.
There are a few different ways that this level of interest in shorting Kodiak Sciences shares can be evaluated.
Kodiak Sciences's "short interest ratio" (SIR) is the quantity of Kodiak Sciences shares currently shorted divided by the average quantity of Kodiak Sciences shares traded daily (recently around 300289.87034036). Kodiak Sciences's SIR currently stands at 12.34. In other words for every 100,000 Kodiak Sciences shares traded daily on the market, roughly 12340 shares are currently held short.
However Kodiak Sciences's short interest can also be evaluated against the total number of Kodiak Sciences shares, or, against the total number of tradable Kodiak Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kodiak Sciences's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Kodiak Sciences shares in existence, roughly 80 shares are currently held short) or 0.1534% of the tradable shares (for every 100,000 tradable Kodiak Sciences shares, roughly 153 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kodiak Sciences.
Find out more about how you can short Kodiak Sciences stock.
We're not expecting Kodiak Sciences to pay a dividend over the next 12 months.
Over the last 12 months, Kodiak Sciences's shares have ranged in value from as little as $18.52 up to $81. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kodiak Sciences's is 1.4009. This would suggest that Kodiak Sciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidate include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases. The company's early research pipeline include KSI-601, a triplet inhibitor for dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.